The Direct Answer: Average Weight Loss at 1 Year

The STEP 1 trial (Wilding et al., NEJM, 2021) reported that participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight at 68 weeks (approximately 16 months). By the 52-week (12-month) mark specifically, the average was approximately 13-15% of body weight.

For practical reference:

• Starting at 200 lbs: approximately 26-30 lbs lost
• Starting at 250 lbs: approximately 32-38 lbs lost
• Starting at 300 lbs: approximately 39-45 lbs lost

The distribution at 12 months tells an important story. In STEP 1, approximately one-third of participants lost 20% or more of their body weight. Roughly 50% lost 15% or more. About 85% achieved the clinically significant threshold of 5%. At the lower end, approximately 10-15% of participants lost less than 5%, indicating a poor response to the medication.

These numbers rival some bariatric surgery outcomes. Gastric banding, for comparison, produces average weight loss of 15-20% at one year. Semaglutide's 14.9% average approaches this range without surgical intervention.

What Clinical Studies Show at 12 Months

STEP 1 (NEJM, 2021): Weight loss continued through week 60, with the curve flattening between weeks 52 and 68. Most participants had reached their maximum weight loss by month 12-14. The separation between semaglutide and placebo was dramatic: semaglutide participants lost 14.9% versus 2.4% for placebo.

STEP 5 (Nature Medicine, 2022): This 104-week study provides the best long-term data. At 52 weeks, average weight loss was 15.2%. Importantly, weight loss was maintained through week 104 with continued treatment, demonstrating that semaglutide's effects are durable as long as the medication continues.

STEP 8 (Nature Medicine, 2022): This head-to-head trial compared semaglutide 2.4 mg to liraglutide 3.0 mg (Saxenda). At 68 weeks, semaglutide produced 15.8% weight loss versus 6.4% for liraglutide. Semaglutide was 2.5 times more effective than its predecessor.

SELECT (NEJM, 2023): In 17,604 participants with cardiovascular disease, semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20%. Weight loss at one year averaged 9.4% in this population, which included many patients on medications that promote weight gain.

Real-world evidence (Obesity, 2024): An analysis of over 36,000 patients prescribed semaglutide found that median 12-month weight loss was 12.3% of body weight. The gap between trial results and real-world results (roughly 2-3 percentage points) reflects differences in adherence, follow-up frequency, and the fact that not all real-world patients reach the full 2.4 mg dose.

The One-Year Transformation: Body and Health

A year of sustained weight loss on semaglutide produces changes across virtually every body system:

• Dramatic physical transformation. Losing 35-50 pounds changes your appearance substantially. Most patients have dropped 3-5 clothing sizes. The change is unmistakable in photos and to everyone in your life.
• Waist circumference. Average reduction of 5-7 inches in STEP trials. This represents a major decrease in visceral fat, the metabolically dangerous fat surrounding abdominal organs.
• Cardiovascular health. Systolic blood pressure reductions of 6-10 mmHg. Triglyceride reductions of 20-30%. CRP (inflammation marker) reductions of 30-40%. These changes collectively reduce 10-year cardiovascular risk significantly.
• Diabetes prevention and management. In the STEP 2 trial, 67% of diabetic participants achieved HbA1c below 7.0%. Among pre-diabetic patients in STEP 1, the majority reverted to normal glucose tolerance. The Diabetes Prevention Program showed that 7% weight loss reduces diabetes risk by 58%; semaglutide patients typically double that threshold.
• Joint health. Osteoarthritis-related pain and disability scores improve significantly with 10-15% weight loss. Many patients reduce or eliminate joint pain medications by the 12-month mark.
• Sleep apnea. A JAMA study (2024) showed AHI reductions of 40-50% with semaglutide. Many patients with moderate sleep apnea no longer require CPAP therapy after sustained weight loss.
• Mental health and quality of life. STEP trial data showed significant, sustained improvements in physical functioning, self-esteem, sexual life, and public distress scores on validated quality-of-life measures at 12 months.
• Liver health. Hepatic steatosis (fatty liver) improves significantly. A sub-analysis showed reductions in liver fat content of 50-60% in patients with NAFLD, with some achieving complete resolution of fatty liver disease.

Factors That Affect Your 1-Year Results

• Dose maintenance. Patients who maintain the full 2.4 mg dose consistently show the best 12-month outcomes. Dose reductions due to side effects or supply issues reduce total weight loss by an average of 3-5 percentage points.
• Body composition strategy. After 12 months of weight loss, the cumulative impact on lean mass becomes significant. Patients who maintained a resistance training program throughout the year preserved substantially more muscle, resulting in a higher metabolic rate and better long-term weight maintenance prospects.
• Metabolic adaptation. Your body's resting metabolic rate decreases as you lose weight. A person who has lost 40 pounds burns roughly 200-300 fewer calories daily than they did at their starting weight. This is a normal adaptation, not a defect, but it means dietary adjustments are needed over time.
• Behavioral changes. Patients who used the appetite reduction from semaglutide as an opportunity to build lasting habits (meal planning, regular exercise, stress management) show better maintenance outcomes than those who relied solely on the medication's appetite effects.
• Psychological factors. A history of emotional eating, binge eating disorder, or significant trauma related to food and body image can affect outcomes. Patients who address these factors (through therapy, support groups, or structured behavioral programs) tend to achieve better results.

Realistic Expectations at One Year

14-15% body weight loss is the clinical benchmark. If you've achieved this, your result matches the average from the most significant obesity medication trial in history. Not everyone reaches this number, and that's okay. Even 10% weight loss produces profound health benefits.

You've likely reached your weight loss plateau. Most patients on semaglutide reach their maximum weight loss between months 12 and 16. The weight loss curve flattens, not because the medication has stopped working, but because your body has reached a new energy equilibrium at the current dose.

Maintenance is now the primary goal. The shift from active weight loss to weight maintenance is a critical transition. The STEP 4 trial demonstrated that discontinuing semaglutide leads to regaining approximately two-thirds of lost weight within one year. Continued treatment is recommended for most patients.

Loose skin is a realistic concern. With 35-50 pounds of weight loss, some degree of skin laxity is common, particularly in patients over 40, those who carried excess weight for many years, and those who lost weight rapidly. This is a cosmetic issue, not a health problem, and various options exist from compression garments to surgical body contouring.

Your relationship with food has fundamentally changed. After a year on semaglutide, most patients have developed an entirely different approach to eating. Portions are smaller, cravings are managed, and the "food noise" that once dominated daily life is quiet. These behavioral patterns can support long-term weight management.

Tips to Maximize Your 1-Year Results

• Comprehensive health assessment. Get full bloodwork at the 12-month mark: metabolic panel, lipid panel, HbA1c, vitamin D, B12, iron studies, thyroid function. Weight loss can reveal or change nutritional deficiencies. Celebrate the improvements in your numbers.
• Reassess your maintenance calories. At your new weight, your calorie needs are significantly lower than at your starting weight. Working with a dietitian to calculate your new maintenance range prevents unintentional undereating (which promotes muscle loss) or creeping calorie increases.
• Prioritize strength training if you haven't. If you focused mainly on cardio during the weight loss phase, now is the time to shift emphasis toward resistance training. Building or rebuilding muscle mass at your new weight supports metabolic health and long-term weight maintenance.
• Discuss long-term medication strategy. Your provider can help determine whether to continue the full 2.4 mg dose, reduce to a maintenance dose, or explore other options. This decision should be based on your individual response, health markers, and goals.
• Address body image adjustment. It takes time for your mental self-image to catch up with physical changes. Some patients experience unexpected emotional responses to their new body. This is normal and worth discussing with a mental health professional if it causes distress.

Frequently Asked Questions

What is the average weight loss after 1 year on semaglutide?

Clinical trial data from the STEP program shows average weight loss of 14.9% of body weight at 68 weeks (approximately 16 months), with roughly 13-15% achieved by the 12-month mark specifically. For a 250 lb person, this means approximately 32-38 lbs. About one-third of patients exceed 20% total weight loss, while roughly 10-15% lose less than 5%.

Will I regain weight if I stop semaglutide after 1 year?

Clinical data strongly suggests yes. The STEP 4 trial showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year of discontinuation. The STEP 5 trial showed that patients who continued treatment maintained their weight loss through 2 years. Most obesity medicine specialists recommend continued long-term treatment, potentially at a reduced dose.

Is 30 pounds in a year a good result on semaglutide?

For most starting weights, 30 pounds at one year represents a strong response. It falls within the range of clinical trial averages (roughly 12-15% of body weight for someone starting at 200-250 lbs). Results above the clinical average are ideal, but even results slightly below average deliver meaningful, measurable health benefits. The 5% threshold is considered clinically significant.

Does semaglutide stop working after a year?

No. Semaglutide does not stop working. What happens is that your body reaches a new energy equilibrium at your lower weight. The medication continues to suppress appetite and regulate blood sugar, which is why patients who discontinue it regain weight. The plateau you experience is the medication working to maintain your new, lower weight against your body's biological drive to return to its previous set point.

Can semaglutide results at 1 year compare to bariatric surgery?

Semaglutide's average weight loss of 14.9% approaches the results of gastric banding (15-20%) but falls short of gastric bypass (25-35%) and gastric sleeve (20-30%). However, semaglutide avoids surgical risks, requires no recovery period, and can be adjusted or discontinued. For patients who are not candidates for or do not want surgery, semaglutide offers the most effective pharmaceutical alternative currently available.

Sustain Your Transformation with Ongoing Support

One year of semaglutide therapy represents a remarkable health achievement. Maintaining those results requires continued medical supervision, dose optimization, and lifestyle support. Form Blends provides physician-supervised telehealth care designed for the long term, with providers who understand both the weight loss and maintenance phases of GLP-1 therapy.

Start your journey with Form Blends